Chiron Capital Management LLC trimmed its holdings in Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 15.0% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 175,965 shares of the biopharmaceutical company’s stock after selling 31,005 shares during the quarter. Bristol Myers Squibb makes up approximately 9.8% of Chiron Capital Management LLC’s holdings, making the stock its biggest position. Chiron Capital Management LLC’s holdings in Bristol Myers Squibb were worth $10,980,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in BMY. Boltwood Capital Management raised its holdings in shares of Bristol Myers Squibb by 2.5% in the 3rd quarter. Boltwood Capital Management now owns 7,107 shares of the biopharmaceutical company’s stock valued at $443,000 after purchasing an additional 170 shares during the period. Sandy Cove Advisors LLC lifted its stake in Bristol Myers Squibb by 4.7% in the 2nd quarter. Sandy Cove Advisors LLC now owns 3,932 shares of the biopharmaceutical company’s stock valued at $227,000 after purchasing an additional 176 shares during the last quarter. Key Financial Inc grew its holdings in Bristol Myers Squibb by 2.4% during the first quarter. Key Financial Inc now owns 7,939 shares of the biopharmaceutical company’s stock worth $482,000 after purchasing an additional 183 shares during the period. Cornerstone Planning Group LLC grew its holdings in Bristol Myers Squibb by 29.8% during the first quarter. Cornerstone Planning Group LLC now owns 801 shares of the biopharmaceutical company’s stock worth $46,000 after purchasing an additional 184 shares during the period. Finally, Rosenberg Matthew Hamilton increased its position in Bristol Myers Squibb by 10.5% during the third quarter. Rosenberg Matthew Hamilton now owns 1,933 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 184 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors.
Key Headlines Impacting Bristol Myers Squibb
Here are the key news stories impacting Bristol Myers Squibb this week:
- Positive Sentiment: Bristol Myers reported encouraging Phase 3 data for RYZ101 in advanced gastroenteropancreatic neuroendocrine tumors, including an improvement in progression-free survival. The results could support upcoming regulatory discussions and strengthen the company’s oncology pipeline. What Could Bristol Myers Squibb Two Phase 3 Wins Change?
- Positive Sentiment: Additional late-stage results for admilparant in idiopathic pulmonary fibrosis were described as showing meaningful clinical benefits and a favorable safety profile. If confirmed, the program could add a new growth opportunity beyond Bristol Myers’ established products. Phase 3 Wins
- Positive Sentiment: Truist maintained a Buy rating, while several articles highlighted BMY’s relatively modest valuation, income potential and history of maintaining dividends through difficult market conditions. Its valuation metrics include a P/E near 13.5 and a PEG ratio below 0.3. Truist Buy Rating
- Neutral Sentiment: BMY became a heavily searched or “trending” stock on Zacks, increasing visibility but providing no fundamental change by itself. Analysts’ opinions remain mixed across comparisons with other healthcare companies. Trending Stock Analysis
- Negative Sentiment: Other coverage characterized the admilparant Phase 3 results as mixed, creating uncertainty about the drug’s ultimate approval prospects and commercial contribution. Investors must also weigh long-term patent expirations and competition affecting blockbuster medicines. Mixed Phase 3 Trial Results
Wall Street Analyst Weigh In
Get Our Latest Analysis on Bristol Myers Squibb
Insider Transactions at Bristol Myers Squibb
In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the company’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the transaction, the senior vice president directly owned 16,862 shares of the company’s stock, valued at $1,138,185. This represents a 2.88% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 0.05% of the stock is owned by company insiders.
Bristol Myers Squibb Stock Performance
Bristol Myers Squibb stock traded up $1.87 during trading hours on Thursday, hitting $61.15. The company had a trading volume of 5,578,121 shares, compared to its average volume of 12,057,397. The firm has a 50-day moving average of $63.72 and a 200 day moving average of $60.28. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. The firm has a market cap of $124.91 billion, a PE ratio of 13.46, a PEG ratio of 0.28 and a beta of 0.19. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $68.64.
Bristol Myers Squibb (NYSE:BMY – Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%. The company had revenue of $12.97 billion during the quarter, compared to analysts’ expectations of $11.74 billion. During the same quarter in the previous year, the company posted $1.46 earnings per share. The business’s revenue was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, sell-side analysts expect that Bristol Myers Squibb Company will post 6.70 earnings per share for the current year.
Bristol Myers Squibb Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Investors of record on Friday, October 2nd will be paid a $0.63 dividend. The ex-dividend date is Friday, October 2nd. This represents a $2.52 annualized dividend and a yield of 4.1%. Bristol Myers Squibb’s payout ratio is 55.51%.
Bristol Myers Squibb Profile
Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its research and commercial activities focus primarily on oncology, hematology, immunology, cardiovascular disease and neuroscience. The company serves patients and healthcare providers in the United States and international markets.
Bristol Myers Squibb’s portfolio includes medicines such as Opdivo and Yervoy for certain cancers, Eliquis for the prevention of blood clots and stroke, Revlimid and Pomalyst for blood cancers, and Abraxane for certain solid tumors.
Featured Stories
- Five stocks we like better than Bristol Myers Squibb
- Beyond the GPU: Credo Paves the Next AI Data Superhighway
- Fastenal Flashes Bullish Signal as Uptrend Holds Despite Margin Pressure
- Synopsys Signals Confidence With $1B Accelerated Buyback, Analysts Raise Targets
- Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But Up
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY – Free Report).
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
